Author + information
- Received May 29, 1991
- Revision received September 4, 1991
- Accepted September 15, 1991
- Published online March 1, 1992.
- ↵*Address for reprints: Sébastien Roux, MD, F. Hoffmann-La Roche, Ltd., Grenzacherstrasse 124, CH-4002 Basel, Switzerland.
Reocclusion of infarct-related coronary arteries within 2 weeks of thrombolytic therapy varies from 5% to 45% and neither clinical nor angiographic variables have been proved to be predictive of reocclusion. The goal of the present study was to evaluate whether aspirin could prevent coronary reocclusion and recurrent ischemia after thrombolysis. For this purpose, a meta-analysis including 32 studies was performed.
Although the studies showed very similar demographic data, the reocclusion rate assessed by angiography in 419 patients treated with aspirin was 11% compared with 25% in 513 patients without aspirin therapy (p < 0.001). Recurrent ischemic events were present in 25% of 2,977 patients treated with aspirin and 41 % of 721 patients treated without aspirin (p < 0.001). The effect of aspirin was similar in trials with either streptokinase or recombinant tissue-type plasminogen activator (rt-PA). Thus, aspirin in the presence of heparin might prevent coronary reoc-clusion after thrombolysis.
- Received May 29, 1991.
- Revision received September 4, 1991.
- Accepted September 15, 1991.
- American College of Cardiology Foundation